Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
CD40 engagement on dendritic cells induces cyclooxygenase-2 and EP2 receptor via p38 and ERK MAPKs.
Harizi H, Limem I, Gualde N.
Immunol Cell Biol. 2011 Feb;89(2):275-82. doi: 10.1038/icb.2010.94. Epub 2010 Aug 10.
Similar articles
Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology.
Harizi H, Corcuff JB, Gualde N.
Trends Mol Med. 2008 Oct;14(10):461-9. doi: 10.1016/j.molmed.2008.08.005. Epub 2008 Sep 4. Review.
[Influenza, an eternal problem].
Barry S, Hessel L, Gualde N.
Can Bull Med Hist. 2007;24(2):445-66. French.
[The black death in Christian and Muslim Occident, 1347-1353].
Barry S, Gualde N.
Can Bull Med Hist. 2008;25(2):461-98. French.
Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators.
Harizi H, Gualde N.
Cell Mol Immunol. 2006 Aug;3(4):271-7. Review.
The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells.
Tissue Antigens. 2005 Jun;65(6):507-14. Review.
Prostanoids and their receptors that modulate dendritic cell-mediated immunity.
Gualde N, Harizi H.
Immunol Cell Biol. 2004 Aug;82(4):353-60. Review.
Eicosanoids: an emerging role in dendritic cell biology.
Arch Immunol Ther Exp (Warsz). 2004 Jan-Feb;52(1):1-5. Review.
Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes.
Harizi H, Grosset C, Gualde N.
J Leukoc Biol. 2003 Jun;73(6):756-63.
Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism.
Harizi H, Juzan M, Moreau JF, Gualde N.
J Immunol. 2003 Jan 1;170(1):139-46.
Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells.
Prostaglandins Leukot Essent Fatty Acids. 2002 May-Jun;66(5-6):459-66.
Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions.
Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N.
J Immunol. 2002 Mar 1;168(5):2255-63.
Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.
Ravaud A, Delaunay M, Chevreau C, Coulon V, Debled M, Bret-Dibat C, Courbon F, Gualde N, Nguyen Bui B.
Br J Cancer. 2001 Nov 16;85(10):1467-71.
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ.
Psychoneuroendocrinology. 2001 Nov;26(8):797-808.
Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells.
Harizi H, Juzan M, Grosset C, Rashedi M, Gualde N.
Cell Immunol. 2001 Apr 10;209(1):19-28.
Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B, Dantzer R, Neveu PJ.
Neuropsychopharmacology. 2001 Feb;24(2):130-40.
In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates.
Coulon V, Ravaud A, Gaston R, Delaunay M, Pariente JL, Verdier D, Scrivante V, Gualde N.
Int J Cancer. 2000 Dec 1;88(5):783-90.
Renal synthesis of leukaemia inhibitory factor (LIF), under normal and inflammatory conditions.
Morel DS, Taupin JL, Potier M, Deminière C, Potaux L, Gualde N, Moreau JF.
Cytokine. 2000 Mar;12(3):265-71.
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network.
Huet S, Marie JP, Gualde N, Robert J.
Cytometry. 1998 Dec 15;34(6):248-56.
Sequential production of leukaemia inhibitory factor by blood cell culture in patients with ARDS.
Gruson D, Hilbert G, Juzan M, Taupin JL, Coulon V, Moreau JF, Gualde N, Gbikpi-Benissan G.
Intensive Care Med. 1998 Apr;24(4):366-8.
Effect of PGE2 on the cell surface molecule expression in PMA treated thymocytes.
Daculsi R, Vaillier D, Carron JC, Gualde N.
Immunol Lett. 1998 Feb;60(2-3):81-8.
Leukemia inhibitory factor: part of a large ingathering family.
Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF.
Int Rev Immunol. 1998;16(3-4):397-426. Review.
Inhibition of graft-versus-host reaction by treatment of immature thymocytes with eicosanoids.
Juzan M, Guibert F, Gualde N.
Prostaglandins Leukot Essent Fatty Acids. 1998 Jan;58(1):69-75.
In vitro production of human antigen presenting cells issued from bone marrow of patients with cancer.
Coulon V, Ravaud A, Huet S, Gualde N.
Hematol Cell Ther. 1997 Oct;39(5):237-44.
Refolding of soluble leukemia inhibitory factor receptor fusion protein (gp 190 sol DAF) from urea.
Liu H, Moreau JF, Gualde N, Fu J.
Mol Cell Biochem. 1997 Apr;169(1-2):43-50.
A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor.
Taupin JL, Gualde N, Moreau JF.
Cytokine. 1997 Feb;9(2):112-8.
Heterogeneity of murine adherent interleukin-2-activated killer cells. Differential effect of prostaglandin E2 and forskolin.
Vaillier D, Daculsi R, Gualde N.
Cancer Immunol Immunother. 1995 Jan;40(1):65-71.
One-year enzyme-linked immunosorbent assay follow-up of human interleukin for Da cells/leukemia inhibitory factor in blood and urine of 22 kidney transplant recipients.
Morel D, Taupin JL, Combe C, Potaux L, Gualde N, Moreau JF.
Transplantation. 1994 Dec 15;58(11):1190-5.
Radiobiological features of acute myeloblastic leukemia: comparison of self-renewal versus terminally differentiated populations.
Cowen D, Richaud P, Landriau S, Lagarde P, Mahon FX, Baudet JJ, Belloc F, Gualde N, Reiffers J.
Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1133-40.
Effect of prostaglandin E2 on cytotoxic activity and granzyme A protease release by murine adherent IL-2 activated killer cells.
Immunobiology. 1994 Apr;190(3):275-89.
Expression of the GST pi gene and response to tamoxifen therapy in locally advanced breast carcinomas.
Dorion-Bonnet F, Quénel N, Coindre JM, Mauriac L, Bonichon F, Durand M, Wafflart J, Moscow JA, Cowan KH, Gualde N.
Ann N Y Acad Sci. 1993 Nov 30;698:182-5. No abstract available.
Regulation by PGE2 of IL-2, IL-3 and IFN production by cortico-resistant thymocytes.
Daculsi R, Vaillier D, Gualde N.
Immunol Lett. 1993 Nov;38(3):229-35.
Functional characterization of liver-associated lymphocytes in patients with liver metastasis.
Winnock M, Garcia-Barcina M, Huet S, Bernard P, Saric J, Bioulac-Sage P, Gualde N, Balabaud C.
Gastroenterology. 1993 Oct;105(4):1152-8.
Immunogenicity of HILDA/LIF either in a soluble or in a membrane anchored form expressed in vivo by recombinant vaccinia viruses.
Taupin JL, Acres B, Dott K, Schmitt D, Kieny MP, Gualde N, Moreau JF.
Scand J Immunol. 1993 Sep;38(3):293-301.
Effect of PGE2 on thymocyte proliferation induced by Con A or IL-4 + PMA.
Daculsi R, Vaillier D, Bezian JH, Gualde N.
Int J Immunopharmacol. 1993 Feb;15(2):195-204.
NZB/NZW F1 mouse nephritis and immune response are not changed by treatment with a 15-lipoxygenase derivative.
Aldigier JC, Cook J, Delebassée S, Guibert F, Touchard G, Juzan M, Gualde N.
Prostaglandins Leukot Essent Fatty Acids. 1992 Oct;47(2):159-64.
Intra-operative electron beam radiotherapy and abdomino-pelvic surgery for cancer: influence on immunological parameters.
Bussières E, Richaud P, Gualde N.
Eur J Surg Oncol. 1992 Oct;18(5):425-32.
5-Lipoxygenase gene expression in the thymus.
Hostein I, Dorion-Bonnet F, Bloch B, Vaillier D, Juzan M, Gualde N.
Thymus. 1992 Sep;20(2):101-8.
Role of thymus-eicosanoids in the immune response.
Juzan M, Hostein I, Gualde N.
Prostaglandins Leukot Essent Fatty Acids. 1992 Aug;46(4):247-55. Review.
HILDA/LIF urinary excretion during acute kidney rejection.
Taupin JL, Morel D, Moreau JF, Gualde N, Potaux L, Bezian JH.
Transplantation. 1992 Mar;53(3):655-8.
Jacalin and artocarpin.
Preud'homme JL, Aucouturier P, Gualde N.
J Immunol Methods. 1992 Feb 5;146(2):259-63. No abstract available.
In vitro study of platelets and circulating mononuclear cells of subjects presenting an intolerance to aspirin.
Guez S, Gualde N, Bezian JH, Cabanieu G.
Int Arch Allergy Immunol. 1992;97(3):233-6.
Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons.
Cancer Immunol Immunother. 1992;35(6):395-400.
Effect of LTB4 on the inhibition of natural cytotoxic activity by PGE2.
Vaillier D, Daculsi R, Gualde N, Bezian JH.
Cell Immunol. 1992 Jan;139(1):248-58.
Influence of LTB4 on CD4-, CD8- thymocytes. Evidence that LTB4 plus IL-2 generate CD8+ suppressor thymocytes involved in tolerance to self. Effect of LTB4 and IL-2 on double negative thymocytes.
Gualde N, Cogny van Weydevelt F, Buffière F, Jauberteau MO, Daculsi R, Vaillier D.
Thymus. 1991 Sep;18(2):111-28.
Human monoclonal IgM with autoantibody activity against two gangliosides (GM1 and GD1b) in a patient with motor neuron syndrome.
Jauberteau MO, Gualde N, Preud'Homme JL, Rigaud M, Gil R, Vallat JM, Baumann N.
Clin Exp Immunol. 1990 May;80(2):186-91.
Purification and characterization of monoclonal antibodies to alpha-linolenic acid.
Buffière F, Cook-Moreau J, Gualde N, Rigaud M.
J Lipid Mediat. 1989 Mar-Apr;1(2):139-47.
Metabolic interactions between eicosanoids in blood and vascular cells.
Lagarde M, Gualde N, Rigaud M.
Biochem J. 1989 Jan 15;257(2):313-20. Review. No abstract available.
Effect of arachidonic acid metabolites on CR1 expression by B-lymphocytes.
Cook JM, Guibert F, Delebassee S, Gualde N.
Int J Immunopharmacol. 1989;11(5):551-8.
A simple in vitro test to evaluate biocompatibility of dialysis membranes.
Vincent D, Charmes JP, Benzakour M, Gualde N, Rigaud M, Leroux-Robert C.
Nephrol Dial Transplant. 1989;4(4):306-8.
Filters: Manage Filters